X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9260) 9260
Newsletter (154) 154
Dissertation (71) 71
Magazine Article (53) 53
Newspaper Article (53) 53
Book Chapter (24) 24
Conference Proceeding (7) 7
Publication (6) 6
Book Review (4) 4
Web Resource (4) 4
Transcript (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
alendronate (6677) 6677
humans (5628) 5628
osteoporosis (4614) 4614
female (4569) 4569
aged (2612) 2612
middle aged (2555) 2555
bisphosphonates (2350) 2350
male (2324) 2324
endocrinology & metabolism (2279) 2279
bone density conservation agents - therapeutic use (1818) 1818
postmenopausal women (1811) 1811
alendronate - therapeutic use (1808) 1808
animals (1730) 1730
bone density - drug effects (1629) 1629
fractures (1593) 1593
osteoporosis - drug therapy (1554) 1554
women (1472) 1472
osteoporosis, postmenopausal - drug therapy (1442) 1442
orthopedics (1437) 1437
bone density (1298) 1298
diphosphonates - therapeutic use (1247) 1247
bone-mineral density (1208) 1208
risk (1199) 1199
aged, 80 and over (1141) 1141
risk factors (1090) 1090
bisphosphonate (1000) 1000
postmenopausal osteoporosis (993) 993
bones (987) 987
bone density conservation agents - administration & dosage (977) 977
bone density conservation agents - adverse effects (961) 961
risedronate (954) 954
prevention (941) 941
therapy (936) 936
alendronate - administration & dosage (927) 927
rats (919) 919
drug therapy (913) 913
rheumatology (891) 891
medicine, general & internal (889) 889
treatment outcome (885) 885
density (877) 877
medicine & public health (869) 869
alendronate - pharmacology (868) 868
adult (863) 863
bone mineral density (828) 828
zoledronic acid (825) 825
alendronate - adverse effects (788) 788
bone (777) 777
research (776) 776
vertebral fractures (752) 752
diphosphonates - administration & dosage (748) 748
pharmacology & pharmacy (742) 742
diphosphonates - adverse effects (735) 735
health aspects (715) 715
care and treatment (672) 672
bone density conservation agents - pharmacology (664) 664
analysis (657) 657
endocrinology (606) 606
diphosphonates - pharmacology (593) 593
mineral density (593) 593
time factors (576) 576
fracture (571) 571
fractures, bone - prevention & control (566) 566
hip fracture (543) 543
diphosphonates (538) 538
randomized-trial (522) 522
surgery (517) 517
bone remodeling - drug effects (509) 509
etidronic acid - analogs & derivatives (505) 505
in-vitro (483) 483
administration, oral (482) 482
drug administration schedule (477) 477
mice (469) 469
absorptiometry, photon (461) 461
double-blind method (458) 458
bone and bones - drug effects (453) 453
dentistry, oral surgery & medicine (449) 449
double-blind (448) 448
risedronate sodium (447) 447
teriparatide (446) 446
denosumab (444) 444
turnover (439) 439
phosphonates (429) 429
retrospective studies (422) 422
parathyroid-hormone (418) 418
medicine, research & experimental (415) 415
abridged index medicus (412) 412
pamidronate (410) 410
resorption (409) 409
dentistry (393) 393
dose-response relationship, drug (393) 393
radiography (390) 390
dosage and administration (388) 388
etidronic acid - therapeutic use (388) 388
follow-up studies (388) 388
osteoporosis - complications (386) 386
biochemical markers (377) 377
osteonecrosis (376) 376
ovariectomy (375) 375
osteoporosis - prevention & control (371) 371
bone resorption (359) 359
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9008) 9008
German (170) 170
Japanese (128) 128
Portuguese (127) 127
Spanish (106) 106
French (73) 73
Korean (45) 45
Chinese (39) 39
Russian (28) 28
Turkish (28) 28
Italian (25) 25
Norwegian (20) 20
Polish (18) 18
Danish (10) 10
Slovak (7) 7
Czech (6) 6
Croatian (5) 5
Dutch (5) 5
Hungarian (4) 4
Swedish (4) 4
Persian (3) 3
Finnish (2) 2
Serbian (2) 2
Slovenian (2) 2
Ukrainian (2) 2
Bulgarian (1) 1
Hebrew (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of allergy and clinical immunology, ISSN 0091-6749, 08/2019, Volume 144, Issue 2, p. 416
for the AsthmaNet Investigators Loss of bronchoprotection (LOBP) with a regularly used long-acting [beta].sub.2-adrenergic receptor agonist (LABA) is well... 
Alendronate
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2004, Volume 350, Issue 12, pp. 1189 - 1199
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 15, pp. 1417 - 1427
Among postmenopausal women with osteoporosis and a high risk of fracture, treatment with the monoclonal antibody romosozumab for 12 months followed by... 
MEDICINE, GENERAL & INTERNAL | METAANALYSIS | BONE-MINERAL DENSITY | VERTEBRAL FRACTURES | DISEASE | AORTA | RANDOMIZED-TRIAL | RISK | STRENGTH | POSTMENOPAUSAL WOMEN | SCLEROSTEOSIS | Humans | Antibodies, Monoclonal - adverse effects | Fractures, Bone - epidemiology | Antibodies, Monoclonal - therapeutic use | Risk | Bone Remodeling - drug effects | Alendronate - therapeutic use | Incidence | Spinal Fractures - prevention & control | Female | Drug Therapy, Combination | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Antibodies, Monoclonal - pharmacology | Spinal Fractures - epidemiology | Bone Density Conservation Agents - therapeutic use | Osteoporosis, Postmenopausal - drug therapy | Bone Density Conservation Agents - pharmacology | Alendronate - adverse effects | Bone Density - drug effects | Alendronate - pharmacology | Least-Squares Analysis | Aged | Cardiovascular Diseases - chemically induced | Fractures, Bone - prevention & control | Treatment outcome | Care and treatment | Fractures | Growth | Analysis | Monoclonal antibodies | Bones | Research | Jaw | Femur | Vertebrae | Immunoglobulins | Inhibitor drugs | Osteonecrosis | SOST protein | Bisphosphonates | Hip | Post-menopause | Bone resorption | Osteoporosis | Alendronic acid | Bone growth | Bone density | Drug therapy | Osteogenesis | randomized-trial | metaanalysis | disease | postmenopausal women | strength | bone-mineral density | Klinisk medicin | vertebral fractures | sclerosteosis | Clinical Medicine | aorta | risk | General & Internal Medicine
Journal Article
Journal of bone and mineral research, ISSN 1523-4681, 2010, Volume 25, Issue 1, pp. 72 - 81
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2007, Volume 357, Issue 20, pp. 2028 - 2039
Journal Article
Biomaterials, ISSN 0142-9612, 2013, Volume 34, Issue 15, pp. 3795 - 3806
Abstract Paclitaxel (PTX) and alendronate (ALN) are effective drugs used for the treatment of breast cancer bone metastases. Growing evidence suggests that... 
Advanced Basic Science | Dentistry | Angiogenesis | Dendrimers | PEG | Bone targeting | Alendronate | Polymer therapeutics | MATERIALS SCIENCE, BIOMATERIALS | ENGINEERING, BIOMEDICAL | PACLITAXEL | MACROMOLECULAR THERAPEUTICS | BISPHOSPHONATES | ANTICANCER | HIGH-RISK | PROSTATE-CANCER | AGENTS | DRUG-DELIVERY SYSTEMS | Neovascularization, Physiologic - drug effects | Paclitaxel - pharmacology | Human Umbilical Vein Endothelial Cells - metabolism | Apoptosis - drug effects | Humans | Bone Neoplasms - secondary | Polyethylene Glycols - chemistry | Antineoplastic Agents - therapeutic use | Paclitaxel - pharmacokinetics | Tibia - pathology | Alendronate - chemistry | Alendronate - therapeutic use | Paclitaxel - chemistry | Human Umbilical Vein Endothelial Cells - cytology | Micelles | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Bone Neoplasms - drug therapy | Alendronate - pharmacokinetics | Tissue Distribution - drug effects | Human Umbilical Vein Endothelial Cells - drug effects | Treatment Outcome | Antineoplastic Agents - chemistry | Tibia - drug effects | Breast Neoplasms - drug therapy | Paclitaxel - therapeutic use | Xenograft Model Antitumor Assays | Animals | Fluorescein-5-isothiocyanate | Breast Neoplasms - pathology | Alendronate - pharmacology | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Ethylene glycol | Care and treatment | Phosphonates | Paclitaxel | Aluminum compounds | Fluorescence | Breast cancer | Metastasis | Drug therapy | Cancer | Index Medicus | Drugs | Imaging | Breast | Bones | Conjugation | Tumors
Journal Article
Journal of bone and mineral research, ISSN 0884-0431, 2010, Volume 25, Issue 8, pp. 1886 - 1894
Journal Article
Osteoporosis international, ISSN 1433-2965, 2011, Volume 23, Issue 1, pp. 317 - 326
The final analysis of this 2-year, randomized, crossover study showed that postmenopausal women with osteoporosis were more adherent, compliant, and persistent... 
Adherence | Persistence | Medicine & Public Health | Alendronate | Compliance | Orthopedics | Gynecology | Rheumatology | Denosumab | Endocrinology | MEDICATION | FRACTURE RATES | OSTEOPOROSIS | LOW BONE MASS | THERAPY | INJECTION | PATIENT PREFERENCE | ENDOCRINOLOGY & METABOLISM | BELIEFS | QUESTIONNAIRE | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Alendronate - therapeutic use | Antibodies, Monoclonal, Humanized | Injections, Subcutaneous | Female | Bone Density Conservation Agents - adverse effects | Drug Administration Schedule | Administration, Oral | Bone Density Conservation Agents - therapeutic use | Treatment Outcome | Patient Preference | Bone Density Conservation Agents - administration & dosage | Osteoporosis, Postmenopausal - drug therapy | Cross-Over Studies | Alendronate - adverse effects | Bone Density - drug effects | Medication Adherence | RANK Ligand - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Osteoporosis, Postmenopausal - physiopathology | Aged | Alendronate - administration & dosage | Patient compliance | Research | Clinical trials | Comparative studies | Drug therapy | Womens health | Alendronic acid | Osteoporosis | Bone mineral density | Tablets | Bisphosphonates | Post-menopause | Original
Journal Article
Osteoporosis international, ISSN 1433-2965, 2015, Volume 27, Issue 1, pp. 21 - 31
We used bone turnover markers to identify women who responded to bisphosphonate treatment for osteoporosis. Response was more likely with alendronate and... 
Bisphosphonate | Medicine & Public Health | Orthopedics | Variability | Rheumatology | Postmenopausal osteoporosis | Bone turnover markers | Endocrinology | BIOCHEMICAL MARKERS | RANDOMIZED-TRIAL | ELDERLY-WOMEN | RISK | FRACTURE INTERVENTION TRIAL | ALENDRONATE THERAPY | MINERAL DENSITY | VERTEBRAL FRACTURES | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | RISEDRONATE | Bone Density - physiology | Humans | Middle Aged | Premenopause - blood | Reference Values | Bone Remodeling - physiology | Bone Remodeling - drug effects | Alendronate - therapeutic use | Risedronate Sodium - therapeutic use | Risedronate Sodium - administration & dosage | Aged, 80 and over | Diphosphonates - therapeutic use | Risedronate Sodium - pharmacology | Adult | Female | Lumbar Vertebrae - physiopathology | Administration, Oral | Bone Density Conservation Agents - therapeutic use | Treatment Outcome | Diphosphonates - administration & dosage | Biomarkers - blood | Bone Density Conservation Agents - administration & dosage | Osteoporosis, Postmenopausal - drug therapy | Bone Density Conservation Agents - pharmacology | Bone Density - drug effects | Alendronate - pharmacology | Osteoporosis, Postmenopausal - physiopathology | Aged | Diphosphonates - pharmacology | Alendronate - administration & dosage | Osteoporosis | Complications and side effects | Patient outcomes | Phosphonates | Development and progression | Postmenopausal women | Research | Health aspects | Bone density | Drug therapy | Menopause | Clinical outcomes
Journal Article
Journal of bone and mineral research, ISSN 0884-0431, 2010, Volume 25, Issue 12, pp. 2558 - 2571